Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Glomerulonephritis
•
Acute kidney injury
How do you manage oral prednisone when initiating nefecon in a patient with IgA nephropathy?
Answer from: at Community Practice
Careful tapering of prednisone and transition planning of budesonide.
Sign In
or
Register
to read more
29009
Related Questions
Do you target specific Kt/V values or specific duration of hemodialysis sessions for hospitalized patients who you are planning several consecutive and progressive hemodialysis initiation sessions?
How do you evaluate for clinically significant ureteral obstruction in a pregnant patient with AKI, since physiological hydronephrosis on kidney ultrasound is common?
Do you use PTH levels to help differentiate CKD from AKI in patients who are being evaluated for an elevated creatinine level and who lack long term lab data?
What factors do you consider when advising a patient with lupus nephritis on the safety of becoming pregnant?
How do you counsel patients who are found to have a carrier mutation in a single high-risk APOL1 allele?
Do you think the benefits of performing a repeat kidney biopsy to assess histologic evidence of disease activity or chronic damage outweigh the risks in a patient with recently treated lupus nephritis and improving creatinine levels?
How do you utilize Cystatin-C as a marker of renal dysfunction in patients with chronic liver disease?
How long would you wait before performing a kidney biopsy in a patient with nephrotic range proteinuria, a negative PLA2R antibody, a negative anti-THSD7A antibody, and stable renal function who recently started treatment a week ago with a DOAC for a pulmonary embolism?
How would you approach the treatment of crescentic fibrillary glomerulonephritis?
How often do you monitor urine protein levels for patients with membranous nephropathy for whom you initiate obinutuzumab?